Application of ionizable lipid compounds in the preparation of nucleic acid drug delivery systems
By using lipid compounds such as Nε-lauroyllysineformamide, a nucleic acid drug delivery system with good lysosomal escape ability was prepared, which solved the problem of low release efficiency of nucleic acid drug in the prior art, and realized the nucleic acid drug in the first 100% Efficient delivery and expression in the body, used to treat diseases such as cancer.
Patent Information
- Application Number
- CN202211314083.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-10-25
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2042-10-25
AI Technical Summary
Existing ionizable lipid compounds perform poorly in lysosomal escape, resulting in low release efficiency of nucleic acid drugs in cells and affecting drug efficacy.
Using Nε-lauroyllysine formamide as an ionizable lipid compound, combined with hydrogenated soybean phosphatidylcholine, cholesterol and distearylphosphatidylethanolamine-polyethylene glycol 2000, a good lysosomal escape was prepared nucleic acid drug delivery system with capability.
It has achieved efficient delivery of nucleic acid drugs to tumor sites in the body, and has significantly improved the expression efficiency of nucleic acids, and is used to treat diseases such as cancer.
Smart Images

Figure CN115957329B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and specifically relates to an application of an ionizable lipid compound in preparing a nucleic acid drug delivery system. Background Art
[0002] Active molecules delivered by nucleic acid drugs include messenger RNA (mRNA), small interfering RNA (siRNA), antisense oligonucleotides (ASO) or plasmid DNA (pDNA), which have great application potential in vaccines and in vitro or in vivo gene therapy. Most nano-drug delivery preparations enter cells by endocytosis. After entering the cell, they first exist in endosomes, which gradually fuse with lysosomes. In order for a drug to exert its efficacy, it must first be released from the nanocarrier, and then, depending on the nature of the drug, some must also be released from the endosome (this process is called endosomal escape). Otherwise, after the fusion of the endosome and the lysosome, the drug will be degraded and inactivated by the lysosome; some drugs are not affected by lysosomal degradation, but must also be released from the lysosome (this process is called lysosomal escape) to allow the drug to be fully released and exert its efficacy. Existing ionizable lipid compounds have poor lysosomal escape, so there is an urgent need for an ionizable lipid compound that can escape from the lysosome. Summary of the invention
[0003] The first aspect of the present invention provides an application of an ionizable lipid compound capable of lysosomal escape in the preparation of a nucleic acid drug delivery system, wherein the ionizable lipid compound is N ε -Lauroyl lysine carboxamide, the structural formula of which is formula (I).
[0004]
[0005] Furthermore, the nucleic acid drug delivery system includes a nucleic acid drug and a delivery liposome; the delivery liposome includes the N ε -lauroyl lysine carboxamide, neutral lipids, structural lipids and polymer conjugated lipids; the N ε -Lauroyl lysine carboxamide can electrostatically adsorb the nucleic acid drug.
[0006] Furthermore, the neutral lipid is hydrogenated soybean phosphatidylcholine; the structural lipid is cholesterol; and the polymer conjugated lipid is distearoyl phosphatidylethanolamine-polyethylene glycol 2000.
[0007] Furthermore, the delivery liposome is composed of N ε -Lauroyl lysine carboxamide: cholesterol: hydrogenated soybean phosphatidylcholine: distearoyl phosphatidylethanolamine-polyethylene glycol 2000 was prepared according to the feed ratio of 1 mg: 1 mg: 1 mg: 1 mg.
[0008] Furthermore, the nucleic acid drug is selected from a combination of one or more of mRNA, siRNA, sgRNA, ASO, circRNA, microRNA, DNA, ecDNA, and artificial nucleic acid.
[0009] Furthermore, the nucleic acid drug is an siRNA with a sequence of Seq_1 that inhibits Stat3 expression.
[0010] Furthermore, the nucleic acid drug delivery system is prepared from Nε-lauroyl lysine carboxamide: cholesterol: hydrogenated soybean phosphatidylcholine: distearoyl phosphatidylethanolamine-polyethylene glycol 2000: siRNA according to a feed ratio of 1 mg: 1 mg: 1 mg: 1 mg: 8.9 nmoL.
[0011] Furthermore, the nucleic acid drug delivery system is a nanolipid particle, the average particle size of the nanolipid particle is 50nm to 200nm, and the polydispersity index of the nanolipid particle is ≤0.4.
[0012] Furthermore, the average size of the nanolipid particles is 50 nm to 150 nm, and the polydispersity index of the nanolipid particles is ≤0.3.
[0013] Furthermore, the ionizable lipid compound may be selectively modified with a targeting substance, wherein the targeting substance is one or more of folic acid, a single-chain antibody or a targeting polypeptide.
[0014] Furthermore, the nucleic acid drug delivery system is used to treat cancer.
[0015] Furthermore, the nucleic acid drug delivery system is used to inhibit lung cancer cells and ovarian cancer cells.
[0016] Furthermore, the administration method of the nucleic acid drug delivery system is injection.
[0017] Furthermore, the nucleic acid drug delivery system is an injection.
[0018] Furthermore, the injection also includes additives, and the additives include stabilizers and / or diluents.
[0019] Furthermore, the additive is added in an amount of 1% to 20% of the total mass of the injection.
[0020] Furthermore, the stabilizer includes but is not limited to sucrose or trehalose.
[0021] Furthermore, the diluent includes one or more of phosphate buffer, acetate buffer, and tris hydrochloride buffer.
[0022] Furthermore, the nucleic acid drug delivery system is administered by local muscle, subcutaneous, endothelial, intravenous injection, intratumoral injection or perfusion.
[0023] The nucleic acid drug delivery system of the present invention can deliver nucleic acid drug delivery molecules such as mRNA, siRNA or pDNA into the body through a variety of administration methods such as local muscle, subcutaneous, endothelial, intratumoral and perfusion, and can also be delivered systemically through intravenous injection and other methods, effectively expressing therapeutic protein drugs or antigens in cells in the body to prevent or treat diseases.
[0024] Compared with the prior art, the present invention has the following beneficial effects:
[0025] The N ε -Lauroyl lysine carboxamide can achieve lysosomal escape, and the N ε -The nucleic acid drug delivery system prepared by lauroyl lysine carboxamide can efficiently deliver nucleic acid drug delivery molecules to tumor sites in vivo and achieve efficient nucleic acid expression.
[0026] The nucleic acid drug delivery system of the present invention can deliver nucleic acid drug delivery molecules such as mRNA, siRNA or pDNA into the body through a variety of administration methods such as local muscle, subcutaneous, endothelial, intratumoral and perfusion, and can also be delivered through systemic administration methods such as intravenous injection, effectively expressing therapeutic protein drugs or antigens in cells in the body, thereby playing a role in preventing or treating diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 N ε -Lauroyl lysine carboxamide 1H NMR spectrum.
[0028] Figure 2 is the mass spectrum of Nε-lauroyl lysine carboxamide;
[0029] Figure 3 Western Blot diagram of drug encapsulation efficiency of nucleic acid drug delivery system (WLNP nanolipid particles).
[0030] Figure 4 Bar graph showing drug encapsulation efficiency of nucleic acid drug delivery system (WLNP nanolipid particles).
[0031] Figure 5 This is a diagram of the drug loading stability of the nucleic acid drug delivery system (WLNP nanolipid particles).
[0032] Figure 6 This is a graph showing the gene silencing efficiency detection of the nucleic acid drug delivery system (WLNP nanolipid particles).
[0033] Figure 7 This is a diagram of in vitro toxicity test of nucleic acid drug delivery system (WLNP nanolipid particles).
[0034] Figure 8 This is a diagram of the targeting detection of the nucleic acid drug delivery system (WLNP nanolipid particles) in animals.
[0035] Fig. 9 Fluorescence image of the lysosomal escape ability of the nucleic acid drug delivery system (WLNP nanolipid particles).
[0036] Fig.10 Bar graph showing the lysosomal escape ability of the nucleic acid drug delivery system (WLNP nanolipid particles). DETAILED DESCRIPTION
[0037] In order to make the contents of the present invention easier to understand, the technical solution of the present invention is further described below in conjunction with specific implementation methods, but the present invention is not limited thereto.
[0038] As used herein, the term "liposome" refers to bilayer nanoparticles composed of phospholipids, cholesterols and functional phospholipids. The phospholipids are selected from one or both of soybean lecithin and egg yolk lecithin. The cholesterol components are selected from one or more of cholesterol and its derivatives, cholestane, bile acid and bile acid. The functional phospholipids are selected from one or more of distearoylphosphatidylethanolamine-polyethylene glycol, distearoylphosphatidylethanolamine-polyethylene glycol, distearoylphosphatidylethanolamine-polyethylene glycol and distearoylphosphatidylethanolamine-polyethylene glycol.
[0039] Unless otherwise defined, all professional terms used below have the same meanings as those generally understood by those skilled in the art. The professional terms used herein are only for the purpose of describing specific embodiments and are not intended to limit the scope of protection of the present invention.
[0040] Experimental Example 1: N ε -Preparation of lauroyl lysine carboxamide (LKN)
[0041] (1) Esterification reaction
[0042] 5g of N α -Benzyloxycarbonyllysine (N α -Cbz-lys, i.e., lysine with α-amino protected by benzyloxycarbonyl) was dissolved in 80 mL of methanol (CH3OH) and stirred in a -10°C ethanol bath for 10-30 min. 6.4 mL of thionyl chloride was added dropwise and stirred at room temperature for 20 h. Excess thionyl chloride, methanol and hydrogen chloride produced in the reaction were removed by evaporation under reduced pressure until a white solid was obtained, which was then dried under vacuum at 50°C to obtain the esterification product N α-Benzyloxycarbonyl lysine ester (N α -Cbz-lysine ester).
[0043] (2) Amidation reaction
[0044] Take 2 g of the esterification product Nα-benzyloxycarbonyl lysine ester from the previous step, dissolve it in 50 ml of concentrated ammonia water, stir and cool it in a -5°C ethanol bath for 24 h, filter it to get a white solid, and dry it in vacuum at 50°C to get the amide reaction product N α -Benzyloxycarbonyl lysinamide (N α -benzyl oxycarbonyl lysine).
[0045] (3) Esterification reaction
[0046] The acylation product of the previous step, 3g of N α -Benzyloxycarbonyl lysinamide and 3mL triethylamine were dissolved in 80mL ethyl acetate and stirred and cooled in a -5℃ ethanol bath for 10-30min, 3mL lauroyl chloride was added dropwise, and the reaction was continued with stirring for 10min, and the reaction was stirred at room temperature for 4h, and the solvent was removed by evaporation under reduced pressure to obtain a crude product of the esterification reaction. The crude product of the esterification reaction was stirred and reacted with a saturated NaHCO3 solution for 15min, the by-product fatty acid was dissolved, and an equal volume of ethyl acetate was used for extraction, the upper ethyl acetate phase was retained, and the ethyl acetate phase was washed with an equal volume of saturated NaCl solution, and the ethyl acetate was removed by evaporation under reduced pressure, and the acylation reaction product was obtained at 50℃ under vacuum drying.
[0047] (4) Deprotection reaction
[0048] Dissolve 3g of the product from the previous step of acylation reaction in 40mL of methanol, add HCl / methanol solution to adjust the pH of the reaction solution to 3-4, and use palladium carbon (10% Pd) as a catalyst to carry out hydrogenation reaction at normal pressure for 4h. Filter the catalyst with diatomaceous earth, and evaporate the solvent under reduced pressure to obtain a crude product without the protecting group (benzyloxycarbonyl). The structure is correct as determined by 1H NMR. The representative 1H NMR spectrum is as follows Figure 1As shown, the specific data are: 1H NMR [400 MHz, DMSO-d6] δ8.17 [s, 3H (-NH3Cl)], 8.01–7.69 [m, 2H (-CONH2)], 7.52 [s, 1H (-NH-)], 3.84–3.61 [m, 1H (–CH2-CH–CONH2)], 3.00 [d, 2H (–CH2–CH2–CH2–CH2–NH–)], 2.03 [t,, 2H (–CH2–CO–NH–)], 1.71 [d, 2H (–CH2–CH2–CH2–CH2–NH–)], 1.56–1.13 [s, 20H m, 2H, (–CH2–CH2–CH2–CH2–CH2–NH–)], 0.85 [t, 3H (CH3–CH2–CH2–)].
[0049] Example 1 Preparation of Nucleic Acid Drug Delivery System (WLNP Nanolipid Particles)
[0050] The preparation method of the nucleic acid delivery system of this embodiment adopts the conventional drop-injection method to prepare liposomes. Take 1 mg hydrogenated soybean phosphatidylcholine (HSPC), 1 mg cholesterol, 1 mg distearoyl phosphatidylethanolamine-polyethylene glycol 2000, 1 mg N ε -lauroyl lysine carboxamide (LKN) was dissolved in 1 mL of methanol, 10 μL of siRNA with a molar concentration of 200 μM was mixed with the above solution at a mass ratio of 1:8, and methanol was added to make a 500 μL solution, and then 100 μL of acetate buffer solution with a pH of 5.0 was added to prepare a liposome mother solution. At this time, N ε The feed ratio of -lauroyl lysine carboxamide: cholesterol: hydrogenated soybean phosphatidylcholine: distearoyl phosphatidylethanolamine-polyethylene glycol 2000: siRNA is 1 mg: 1 mg: 1 mg: 8.9 nmol. The siRNA is the siRNA with the sequence Seq_1 that inhibits the expression of Stat3.
[0051] Seq_1: 5'-TCGACTGCATAGGACGGAATGAACAAGCGTTCATTCC GTCCTATGCATTTTTT-3'.
[0052] Preheat 400 μL of Dulbecco's phosphate buffer (DPBS) at 55°C for 5 minutes, and slowly inject the liposome mother solution into DPBS under stirring, heat for about 1 hour, and use a rotary evaporator to reduce pressure in a 45°C water bath to form a thin film in the bottle, and then use a vacuum pump to completely remove methanol. Ultrasonicate 3-4 times in an ice water bath (2 seconds for each ultrasound and 3 seconds for each stop), purify, and obtain a transparent liquid with opalescence, that is, a nucleic acid drug delivery system (WLNP nanolipid particles), which is stored in a 4°C refrigerator for use. The nucleic acid drug delivery system was measured in PBS and complete culture medium using a Malvern laser particle size analyzer, and the particle size was 90-150nm and the polydispersity coefficient was 0.25-0.29.
[0053] Example 2 Determination of drug encapsulation efficiency of nucleic acid drug delivery system (WLNP nanolipid particles)
[0054] The control group was 4 μL siRNA dissolved in 200 μL methanol, and the experimental group was purified and the same amount of WLNP liposome stock solution as the control group siRNA was added. 2 mg heparin and 200 μL methanol were added respectively, and ultrasonic cell disruptor was used in an ice water bath for 5 minutes. 6× loading buffer was added to the control group and the experimental group at a volume ratio of 1:5, and after mixing evenly, 70-120V voltage, electrophoresis for 20-40 minutes, and photographed with a gel imager. The results are shown in Figure 2 As shown in the figure, the higher the brightness of the free siRNA band in the gel imager, the more free siRNA there is. Image J was used to calculate the gray value of the two parts and the encapsulation rate was calculated. The results are shown in Figure 3 , 4 As shown on the right, the drug encapsulation efficiency of WLNP liposomes can reach 65%.
[0055] Example 3 Drug loading stability test of nucleic acid drug delivery system (WLNP nanolipid particles)
[0056] After the drug-loaded liposome stock solution was prepared, it was diluted with 0.01M pH 7.4 PBS and serum-containing complete cell culture medium to a drug-containing siRNA concentration of 100 μM. Samples were taken every 24 hours and the liposome particle size and potential were measured using a Malvern laser particle size analyzer. The results are shown in Figure 5 As shown, using N ε -The particle size and potential of the liposomes of lauroyl lysine carboxamide maintained a dynamic equilibrium, indicating that the siRNA loading in the liposomes was very stable.
[0057] The study found that N ε -Lauroyl lysine carboxamide liposome encapsulation efficiency is not only high but also very stable, mainly due to N ε-Lauroyl lysine carboxamide is a typical amphiphilic molecule (with a non-polar long acyl chain and a polar end α-NH2) and has poor water solubility, so it has a strong affinity with phospholipid molecules, binds tightly, and is not easy to leak out prematurely.
[0058] Example 4 Detection of gene silencing efficiency of nucleic acid drug delivery system (WLNP nanolipid particles)
[0059] The expression level of STAT3 mRNA after siRNA incubation of 293T cells for 48 hours is as follows:
[0060] 293T cells were seeded at 3×10 per well. 5 The cells were inoculated into 6-well plates for incubation. After 24 hours, when the cells adhered to the wall and grew stably, the culture medium was aspirated. The control group was free siRNA and WLNP liposomes without siRNA prepared in reference to Example 1. The siRNA concentrations of the experimental group were 50nM and 100nM, respectively, and the incubation was continued for 48 hours. Cell RNA was extracted by Trizol method, and the expression level of STAT3 siRNA in 293T cells was detected by qPCR.
[0061] The results are as follows Figure 6 As shown, compared with the control group and the group without siRNA, the expression level of STAT3 siRNA in the drug group was significantly decreased, and as the drug concentration increased, the expression level of siRNA continued to decrease (statistical analysis showed differences, ** represents P < 0.01, *** represents P < 0.001 vs CON), indicating that WLNP liposomes can successfully deliver siRNA to cells and perform gene silencing.
[0062] Example 5 In vitro toxicity test of WLNP nanolipid particles
[0063] CCK-8 cell activity test of the drug, specifically:
[0064] Ovarian cancer cells SKOV3 and normal ovarian epithelial cells IOSE were cultured at 10 4 The number of cells was inoculated into 96-well plates for incubation. After 24 h, when the cells adhered to the wall and grew stably, the medium was aspirated and 100 μL of liposome stock solution diluted with the medium was added to make N ε The final concentrations of -lauroyl lysine carboxamide were 20μM, 40μM, 60μM, 80μM, and 100μM, respectively, and the incubation was continued for 48h. According to the instructions for the reagent, the culture medium was aspirated, and 100μL of 0.5mg / mL CCK-8 reagent was added to each well. After incubation for 1h, the absorbance of each well was recorded at 450nm using a microplate reader, and the cell survival rate was calculated as follows:
[0065]
[0066] A0, A1, and A2 are the absorbances of the blank group (pure culture medium without liposomes), the drug-loaded liposome group (cells treated with drug-loaded liposomes), and the control group (cells treated with blank liposomes), respectively.
[0067] The results are as follows Figure 7 As shown, when the drug concentration increased, the survival rate of ovarian cancer cells SKOV3 and normal ovarian epithelial cells IOSE had almost no significant decrease except for the group with a drug concentration of 100 μM, indicating that WLNP nanolipid particles as a delivery system have basically no toxicity when the concentration is below 80 μM.
[0068] Example 6: In vivo targeting detection of WLNP-siRNA-cy5 nanolipid particles in animals
[0069] The WLNP-siRNA-cy5 nanolipid particles in the experimental group were prepared according to the preparation method of Example 1, and the liposome environment was quickly converted using 200 μL of neutral PBS buffer. The control group was free siRNA-cy5, and the other conditions were the same. They were injected into the tail vein of 6-8 week old female Babl / c mice that were successfully inoculated with lung cancer A549 cells. 50 μg siRNA was injected intravenously. The fluorescence expression of each organ of the mice 4 hours after intravenous injection of WLNP-siRNA-cy5 is shown in Figure 8 The results showed that the fluorescence expression of siRNA-cy5 in the control group was almost zero in mouse tumors, while the WLNP-siRNA-cy5 nanolipid particles in the experimental group were expressed in mouse tumors, indicating that WLNP-siRNA-cy5 nanolipid particles have a certain targeting effect.
[0070] Example 7 Detection of the lysosomal escape ability of WLNP-siRNA-cy5 nanolipid particles
[0071] A549 cells (lung cancer cells) were seeded at 8×10 3 The number of cells was inoculated into 96-well plates for incubation. After 24 hours, when the cells attached to the wall and grew stably, the medium was aspirated, Hoechst 33342 was added for staining for 10 minutes, and then Lyso-Tracker Green was added for staining for 15 minutes. 100 μL of liposome stock solution diluted with culture medium was added to the experimental group, and cationic liposomes were used instead of N in the control group. ε -lauroyl lysine formamide, all other conditions were the same, incubated for 10 min, washed, and photographed every 20 min for 2 h at high content.
[0072] The results are as follows Fig. 9 , 10As shown, the green position is the lysosome, and the red is the WLNP-siRNA-cy5 nanolipid particle. The part where the red does not overlap with the green is the lipid particle that has escaped from the lysosome. The lysosomal escape rate of the drug in the experimental group is about 42%, and the lysosomal escape rate of the control group is about 7%. The experimental group is 6 times that of the control group, proving that the WLNP-siRNA-cy5 nanolipid particles have good lysosomal ability.
[0073] In summary: N ε -Lauroyl lysine carboxamide enables lysosomal escape, composed of N ε -The nucleic acid drug delivery system prepared by lauroyl lysine carboxamide can efficiently deliver nucleic acid drug delivery molecules to tumor sites in vivo and achieve efficient nucleic acid expression.
[0074] Although the present invention has been illustrated and described with specific embodiments, it will be appreciated that many other changes and modifications may be made without departing from the spirit and scope of the present invention. Therefore, it is intended to include all such changes and modifications within the scope of the present invention in the appended claims.
Claims
1. Use of an ionizable lipid compound in the preparation of a nucleic acid drug delivery system, characterized in that: The ionizable lipid compound is N ε -lauroyl lysine carboxamide, the structural formula of which is formula (I), Formula (I), the nucleic acid drug delivery system comprises a nucleic acid drug and a delivery liposome; the delivery liposome comprises the N ε -lauroyl lysine carboxamide, neutral lipids, structural lipids and polymer conjugated lipids; the N ε -Lauroyl lysine carboxamide can electrostatically adsorb the nucleic acid drug; The neutral lipid is hydrogenated soybean phosphatidylcholine; the structural lipid is cholesterol; the polymer conjugated lipid is distearoyl phosphatidylethanolamine-polyethylene glycol 2000; and the nucleic acid drug is selected from siRNA.
2. The use according to claim 1, characterized in that: The delivery liposomes are composed of N ε -Lauroyl lysine carboxamide: cholesterol: hydrogenated soybean phosphatidylcholine: distearoyl phosphatidylethanolamine-polyethylene glycol 2000 was prepared according to the feed ratio of 1 mg: 1 mg: 1 mg: 1 mg.
3. The use according to claim 2, characterized in that: The nucleic acid drug delivery system comprises N ε -Lauroyl lysine carboxamide: cholesterol: hydrogenated soybean phosphatidylcholine: distearoyl phosphatidylethanolamine-polyethylene glycol 2000: siRNA were prepared according to the feed ratio of 1 mg: 1 mg: 1 mg: 1 mg: 8.9 nmoL.
4. The use according to claim 1, characterized in that: The nucleic acid drug is an siRNA with a sequence of Seq_1 that inhibits the expression of Stat3.
5. The use according to any one of claims 1 to 4, characterized in that: The nucleic acid drug delivery system is used to prepare drugs for treating cancer; the drugs for treating cancer are used to inhibit lung cancer cells or ovarian cancer cells.
6. The use according to any one of claims 1 to 4, characterized in that: The administration method of the nucleic acid drug delivery system is injection.
